Company
Medicus Pharma
NASDAQ:MDCX
Medicus Pharma (NASDAQ:MDCX) is a clinical stage holding company focused on investing in and accelerating novel life sciences and biotechnology companies. Skinject, Inc., a wholly owned subsidiary of Medicus Pharma, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell and squamous cell skin cancer using patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumors cells. The company currently has an FDA approved phase 2 trial actively recruiting patients.
92 stories
Medicus Pharma reports positive Phase 2 data for SkinJect in skin cancer treatment
Medicus Pharma (NASDAQ:MDCX) said a completed Phase 2 study of its SkinJect therapy showed all 90 enrolled patients finished treatment without...
Dow closes lower as Wall Street falls for fourth straight day
4:15pm: Another day of losses Wall Street closed lower for a fourth straight session on Thursday as investors digested fresh wholesale inflation data and...
Dow closes sharply lower as oil surge fuels inflation fears
4:15pm: Oil spike hits stocks US stocks closed sharply lower on Tuesday as surging oil prices revived inflation worries and pushed investors to reassess the...
Medicus Pharma reorients around new cancer drug candidate, sharpens focus for other programs
Medicus Pharma (NASDAQ:MDCX) is repositioning itself as a precision oncology-led biotechnology company, centering its strategy on CD228V, a...